Apimeds Pharmaceuticals US, Inc. (APUS)
(Delayed Data from AMEX)
$1.79 USD
-0.11 (-5.79%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $1.79 0.00 (0.00%) 4:56 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APUS 1.79 -0.11(-5.79%)
Will APUS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APUS based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for APUS
50 Day Moving Average Support appears for APUS after 5.94% move
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
APUS falls 2.88% on September 15, leaving the technical picture intact
APUS forms Pocket Pivot on September 12
Is APUS ready to move higher? 20 Day Moving Average Support shows up after declining 3.96%